New hair loss pill shows promise in early trial

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Subject is male or non-pregnant female aged 18-65 years old; * Subject has a clinical diagnosis of mild to moderate AGA; * Subject is in good general health and has normal renal and hepatic function; * Subject is willing to maintain at least 1/4 inch length hair during the study with the same hairstyle, hair length, and hair color throughout the study; maintain consistent use of general hair care products and regimen through the entire study; * Subject is willing and able to administer the test article as directed read, understand, and complete required questionnaires in English; * Subject agrees to have a micro dot tattoo placed on their scalp; * Subject agrees to have this area photographed at study visits as indicated in the protocol. Exclusion Criteria: * Subject has uncontrolled blood pressure; * Subject has symptoms or history of certain heart or thyroid conditions; * Subject has a history of cardiac and/or thyroid diseases; * Subject has received an organ transplant; * Subject has a history of prescription drug abuse or illicit drug use within 6 months of screening; history of alcohol abuse within 6 months prior to screening; * Subject has a current or recent history of dietary or weight changes; * Subject has been diagnosed with COVID-19 within 16 weeks of baseline; * Subject has used any topical scalp treatments for hair growth within 4 weeks prior to screening; * Subject has had any scalp procedures, including surgical, laser, light or energy treatments, micro-needling, etc. within 6 months prior to screening; * Subject has had previous radiation of the scalp; * Subject has used systemic cimetidine, ketoconazole, diazoxide, or corticosteroids (including intramuscular, intraarticular, and intralesional injections) within 12 weeks prior to screening; * Subject has used systemic beta blockers within 12 weeks prior to screening; * Subject is currently enrolled in an investigational drug, biologic, or device study or has used an investigational treatment within 30 days prior to screening; * Subject has used any other therapy with any medication either topical or oral that might, in the investigator's opinion, interfere with the study.